NAUT · 10-Q · 2026Q1 · Full report

Interest Rate and Refinancing Exposure

Nautilus Biotechnology, Inc. · 2026-04-28 · Importance 40 · Surprise 56

Other income declined as interest income fell to $1.442 million for the three months ended March 31, 2026 from $2.231 million in the prior-year period, a 35% decrease ($0.789 million) attributed to a lower cash/investments balance and decreased yield rates on investments. The decrease in interest income reduced total other income and contributed to the reported net loss for the quarter. Management identifies changing interest rates as a macro risk factor that could influence yields on cash and short-term investments and, separately, its ability to access capital markets on favorable terms. The company continues to use its cash and marketable securities to fund operations while monitoring market yields and liquidity options.

Key facts

• Any future debt financing Nautilus may enter could impose covenants restricting operations, including limits on liens or additional debt, dividend payments, repurchases of common stock, certain investments, and certain merger, consolidation or asset sale transactions.

Impact estimates